Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
A critical appraisal of the STEP-1 semaglutide 2.4 mg trial, covering enrollment biases, generalizability gaps, follow-up duration, statistical methods, industry funding, and post-publication commentary.
Read clinical reviewDeep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from STEP-1: cost per QALY, payer coverage gaps, list vs net pricing, and value calculations for patients considering treatment.
Read clinical reviewA deep dive into the STEP-1 trial's primary and secondary endpoints for semaglutide 2.4 mg, including effect sizes, confidence intervals, response distribution, and week-by-week weight-loss trajectory.
Read clinical reviewDeep dive into STEP-1 pre-specified and post-hoc subgroup analyses by age, sex, BMI, race, and baseline biomarkers, revealing which patients lost the most weight on semaglutide 2.4 mg.
Read clinical reviewA deep-dive into the STEP-1 trial (2021 NEJM) that demonstrated 14.9% mean body weight loss with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks in adults with obesity.
Read clinical review